Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 9 of 408 for:    ARIPIPRAZOLE

Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Tourette's Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03487783
Recruitment Status : Recruiting
First Posted : April 4, 2018
Last Update Posted : February 22, 2019
Sponsor:
Information provided by (Responsible Party):
Otsuka Beijing Research Institute

Brief Summary:
This study is a multicenter, randomized, double-blind, placebo-controlled trial designed to assess the safety, efficacy, tolerability and steady-state plasma trough concentration of flexible-dosed aripiprazole once-daily administration in children and adolescents with Tourette's syndrome. A total of around 120 subjects will be randomized to aripiprazole (2~20 mg) or placebo in a 1:1 ratio (approximately 60 subjects in each group), for treatment of 8 weeks.

Condition or disease Intervention/treatment Phase
Tourette Syndrome Drug: Aripiprazole Oral Solution Drug: Placebo Oral Solution Phase 3

Detailed Description:

Screening phase: It can last up to 42 days, including the screening visit (V1), a washout period when applicable, additional screening visit (V1a) and baseline visit (V2). The screening phase will serve the following purposes: 1) To allow for appropriate washout of prohibited medications; 2) To review the screening data; 3) To establish a pretreatment baseline of critical outcome measures.

Treatment phase: It lasts 8 weeks; the purpose of the treatment phase is to assess the efficacy, safety, tolerability and steady-state plasma trough concentration of aripiprazole in the treatment of children and adolescents with Tourette's syndrome.

Safety follow-up phase: All subjects will be followed up for safety (adverse events) at Day 16 after the final medication via telephone


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Flexible-Dosed, Placebo-Controlled, Parallel-Group Clinical Trial Evaluating the Efficacy and Safety of Aripiprazole Oral Solution in Children and Adolescents With Tourette's Syndrome
Actual Study Start Date : May 2, 2018
Estimated Primary Completion Date : April 2020
Estimated Study Completion Date : April 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Aripiprazole Oral Solution
1 mg/mL, 2-20 mg/day (2-20 mL/day), once daily for 8 weeks, administered at about the same time every day, either before or after meal
Drug: Aripiprazole Oral Solution
Aripiprazole 2-20 mg/day (2-20 mL/day)
Other Names:
  • Aripiprazole OS
  • Abilify

Placebo Comparator: Placebo Oral Solution
2-20 mg/day (2-20 mL/day), once daily for 8 weeks, administered at about the same time every day, either before or after meal
Drug: Placebo Oral Solution
Placebo 2-20 mg/day (2-20 mL/day)
Other Name: Placebo




Primary Outcome Measures :
  1. Changes from Baseline to Week 8 (or endpoint) in YGTSS TTS. [ Time Frame: Baseline and 8 weeks (or endpoint) ]
    The objective of the primary analysis is to compare the efficacy of flexible-dosed aripiprazole oral solution (2~20 mg/day) with placebo in the suppression of tics in children and adolescents with a diagnosis of Tourette's syndrome. The efficacy is assessed by the changes of total tic scores (TTS) from randomization to the last visit (Week 8) on the Yale Global Tic Severity Scale (YGTSS).


Secondary Outcome Measures :
  1. Percentage change from Baseline to Week 8 (or endpoint) in YGTSS TTS; [ Time Frame: Baseline and 8 weeks (or endpoint) ]
    The efficacy is assessed by the percentage subjects changes of total tic scores (TTS) from randomization to the last visit (Week 8) on the Yale Global Tic Severity Scale (YGTSS)

  2. Response rate on TS-CGI Improvement scale [ Time Frame: Baseline and 8 weeks (or endpoint) ]
    The response rate (the percentage of patients with a score of 1 or 2) is assessed by TS-CGI Improvement scale from Baseline to Week 8 (or endpoint)

  3. Partial remission rate on TS-CGI Improvement scale [ Time Frame: Baseline and 8 weeks (or endpoint) ]
    The partial remission rate (the percentage of patients with a score of 3) is assessed by TS-CGI Improvement scale from Baseline to Week 8 (or endpoint)

  4. Changes from Baseline to Week 8 (or endpoint) in TS-CGI Severity scale scores [ Time Frame: Baseline and 8 weeks (or endpoint) ]
    The efficacy is assessed by changes from Baseline to Week 8 (or endpoint) in TS-CGI Severity scale scores



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   6 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Written informed consent form must be obtained from a legal guardian (and the subject)
  2. The subject and the designated guardian(s) or caregiver(s) are able to comprehend and satisfactorily comply with the protocol requirements, as evaluated by the investigator.
  3. The subject is a male or female child or adolescent, 6-18 years of age (6≤ Age <18) at the time of Baseline Visit (V2);
  4. The subject meets the current DSM-IV-TR diagnostic criteria for Tourette's syndrome and requires drug therapy;
  5. The subject has a TTS ≥ 22 on the YGTSS at Baseline Visit (V2);

Exclusion Criteria:

  1. Women of childbearing potential (WOCBP) who will not commit to utilizing the approved birth control methods or who will not remain abstinent during the trial and for 8 weeks following the final dose of study drug; Note: WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not postmenopausal [defined as amenorrhea 12 consecutive months; or women on hormone replacement therapy with documented serum follicle stimulating hormone level ≥ 35 mIU/mL].
  2. Females who have a positive pregnancy test result or who are pregnant or breast-feeding;
  3. Subjects who have secondary tic symptoms accompanied by late-onset tics, Huntington's chorea, neuroacanthocytosis, mental retardation, or autism;
  4. Subjects who have comorbidities requiring drug therapy, such as attention deficit / attention-deficit hyperactivity, obsessive-compulsive disorder, or oppositional defiant disorder (if a case is judged by the investigator that drug therapy is not required for any of the above diseases during this study, then the patient is eligible to participate in this trial);
  5. Subjects who have lower intelligence;
  6. Subjects who have a current diagnosis of bipolar disorder, mental disorder, schizophrenia, or depressive disorder;
  7. Subjects who have records of neuroleptic malignant syndrome;
  8. Subjects who have experienced episodes of epileptic seizure in the past year;
  9. Subjects who have a history of severe traumatic brain injury or stroke;
  10. Subjects who have any unstable medical conditions or are currently ill (e.g., congenital heart disease, arrhythmia or cancer), which, in the investigator's judgment, will put them at a risk of major adverse event during this trial, or will interfere with safety and efficacy assessments
  11. Subjects who require both drug therapy and cognitive-behavioral therapy (CBT, including habitual inversion therapy, cognitive therapy, relaxation training, etc.) during the trial period;
  12. Patients with the following laboratory test results, vital signs, measurements, and electrocardiogram (ECG) results will be excluded:

    • QTc > 450 msec (male), QTc > 470 msec (female)
    • Platelets (< lower limit)
    • Hemoglobin (< lower limit)
    • Neutrophils (< lower limit)
    • AST (SGOT) or ALT (SGPT) (> upper limit)
    • Creatinine (> upper limit) Subjects should be excluded if they have any other abnormal laboratory tests, vital sign results, or ECG findings which in the investigator's judgment is medically significant and will impact the safety of the subject or the interpretation of the trial results;
  13. Subjects who have a body weight of lower than 15 kg;
  14. Subjects who have been known to be with allergy or hypersensitivity to aripiprazole or other dihydroquinolones (e.g., carteolol, vesnarinone and cilostazol);
  15. Subjects who have participated in any clinical trial of any drugs within the past one month;
  16. Subjects who may require concomitant treatments prohibited as per the protocol during the trial period (referring to Section 7 Prohibited and Restricted Therapies);
  17. Subjects who were previously enrolled in clinical trials of aripiprazole (excluding investigator-sponsored trials);
  18. Subjects who are considered to have developed resistance to antipsychotic drugs by the investigator due to lack of efficacy after receiving 2 different antipsychotic drugs at reasonable doses and at least 3 weeks of treatment with each respectively;
  19. Subjects who are considered to have developed resistance to aripiprazole by the investigator due to lack of efficacy after an adequate time of treatment with adequate dose;

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03487783


Contacts
Layout table for location contacts
Contact: Wenwen Xu 010-85182966 xuww@obri.otsuka.com

Locations
Layout table for location information
China, Beijing
Beijing Anding Hospital of Capital Medical University Recruiting
Beijing, Beijing, China, 100088
Contact: Hongli Lang, Master         
Principal Investigator: Yi Zheng, MD         
Sponsors and Collaborators
Otsuka Beijing Research Institute
Investigators
Layout table for investigator information
Study Director: Patyman Juma Otsuka Beijing Research Institute

Layout table for additonal information
Responsible Party: Otsuka Beijing Research Institute
ClinicalTrials.gov Identifier: NCT03487783     History of Changes
Other Study ID Numbers: 031-403-00107
First Posted: April 4, 2018    Key Record Dates
Last Update Posted: February 22, 2019
Last Verified: September 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Otsuka Beijing Research Institute:
Tourette
Aripiprazole Oral Solution
Additional relevant MeSH terms:
Layout table for MeSH terms
Aripiprazole
Tourette Syndrome
Syndrome
Disease
Pathologic Processes
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tic Disorders
Movement Disorders
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Genetic Diseases, Inborn
Neurodevelopmental Disorders
Mental Disorders
Pharmaceutical Solutions
Antidepressive Agents
Psychotropic Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Dopamine Agonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Serotonin 5-HT1 Receptor Agonists
Serotonin Receptor Agonists
Serotonin Agents